DiscoverThe Lancet in conversation withPresented at ESMO: the HARMONi-6 study on a bispecific antibody therapy for squamous NSCLC
Presented at ESMO: the HARMONi-6 study on a bispecific antibody therapy for squamous NSCLC

Presented at ESMO: the HARMONi-6 study on a bispecific antibody therapy for squamous NSCLC

Update: 2025-10-19
Share

Description

Shun Lu joins Ben Abbott of The Lancet to discuss the phase 3 HARMONi-6 trial of ivonescimab plus chemotherapy as first-line treatment in advanced squamous non-small-cell lung cancer, which is being presented at ESMO 2025.

Click here to read the full article

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

Comments 
In Channel
ASCO 2025 Debrief

ASCO 2025 Debrief

2025-06-1115:14

Previewing ASCO 2025

Previewing ASCO 2025

2025-05-3005:24

loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Presented at ESMO: the HARMONi-6 study on a bispecific antibody therapy for squamous NSCLC

Presented at ESMO: the HARMONi-6 study on a bispecific antibody therapy for squamous NSCLC

The Lancet Group